[go: up one dir, main page]

DE60317198D1 - Proteinkinaseinhibitoren - Google Patents

Proteinkinaseinhibitoren

Info

Publication number
DE60317198D1
DE60317198D1 DE60317198T DE60317198T DE60317198D1 DE 60317198 D1 DE60317198 D1 DE 60317198D1 DE 60317198 T DE60317198 T DE 60317198T DE 60317198 T DE60317198 T DE 60317198T DE 60317198 D1 DE60317198 D1 DE 60317198D1
Authority
DE
Germany
Prior art keywords
protein kinase
kinase inhibitors
compound
formula
diastereomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60317198T
Other languages
English (en)
Other versions
DE60317198T2 (de
Inventor
Christopher John Burns
Xianyong Bu
Andrew Frederick Wilks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YM Biosciences Australia Pty Ltd
Original Assignee
Cytopia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPS2515A external-priority patent/AUPS251502A0/en
Application filed by Cytopia Pty Ltd filed Critical Cytopia Pty Ltd
Application granted granted Critical
Publication of DE60317198D1 publication Critical patent/DE60317198D1/de
Publication of DE60317198T2 publication Critical patent/DE60317198T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
DE60317198T 2002-05-23 2003-05-23 Proteinkinaseinhibitoren Expired - Lifetime DE60317198T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPS251502 2002-05-23
AUPS2515A AUPS251502A0 (en) 2002-05-23 2002-05-23 Protein kinase inhibitors
US39907002P 2002-07-26 2002-07-26
US399070P 2002-07-26
PCT/AU2003/000629 WO2003099796A1 (en) 2002-05-23 2003-05-23 Protein kinase inhibitors

Publications (2)

Publication Number Publication Date
DE60317198D1 true DE60317198D1 (de) 2007-12-13
DE60317198T2 DE60317198T2 (de) 2008-12-04

Family

ID=29585026

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60317198T Expired - Lifetime DE60317198T2 (de) 2002-05-23 2003-05-23 Proteinkinaseinhibitoren

Country Status (10)

Country Link
US (2) US7122550B2 (de)
EP (1) EP1513821B1 (de)
CN (1) CN100558715C (de)
AT (1) ATE377004T1 (de)
CA (1) CA2486183C (de)
DE (1) DE60317198T2 (de)
GB (1) GB2392154B (de)
IL (2) IL165264A0 (de)
NZ (1) NZ537155A (de)
WO (1) WO2003099796A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003179A1 (en) * 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
AU2002953255A0 (en) * 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
EP1644365A2 (de) * 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazin- und pyridinderivative als rho-kinase-inhibitoren
CA2540640A1 (en) * 2003-09-30 2005-04-14 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CN102127056B (zh) * 2003-12-03 2013-08-21 Ym生物科学澳大利亚私人有限公司 微管蛋白抑制剂
EP1694670A1 (de) * 2003-12-16 2006-08-30 GPC Biotech AG Pyrazinderivate als gegen infektionskrankheiten wirksame verbindungen
ES2611604T3 (es) * 2004-10-22 2017-05-09 Janssen Pharmaceutica Nv Inhibidores de la c fms quinasa
JP2008519814A (ja) * 2004-11-12 2008-06-12 ガラパゴス・ナムローゼ・フェンノートシャップ プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
EP2343298B9 (de) 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroarylsubstituierte Pyrrolo[2,3-b]Pyridine und Pyrrolo[2,3-b]Pyrimidine als Januskinaseinhibitoren
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
WO2007124319A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
AU2007240437B2 (en) 2006-04-20 2012-12-06 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
EP2044051B1 (de) * 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
AU2013273769B2 (en) * 2006-11-15 2016-05-12 Ym Biosciences Australia Pty Ltd Inhibitors of Kinase Activity
PL2848610T3 (pl) * 2006-11-15 2018-01-31 Ym Biosciences Australia Pty Inhibitory aktywności kinazy
DK2152701T3 (en) 2007-03-12 2016-02-15 Ym Biosciences Australia Pty Phenylaminopyrimidinforbindelser and uses thereof
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
WO2009046141A2 (en) 2007-10-01 2009-04-09 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
PL2252597T3 (pl) * 2008-02-01 2014-09-30 Akinion Pharmaceuticals Ab Pochodne pirazyny i ich zastosowanie jako inhibitorów kinaz białkowych
JP2011519926A (ja) * 2008-05-05 2011-07-14 ウィンスロップ−ユニバーシティー ホスピタル Ｃｏｘ阻害薬の心血管系リスク因子の改善方法
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US8652787B2 (en) 2008-11-12 2014-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ERBB4 as a prognostic and therapeutic marker for melanoma
CN101475563B (zh) * 2008-11-21 2012-11-14 东华大学 3-氨基-4-吲哚-n-甲基马来酰亚胺化合物、其制备及应用
HRP20192203T1 (hr) 2009-05-22 2020-03-06 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2338888A1 (de) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridin-Derivate als JAK-Inhibitoren
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
US9168297B2 (en) 2010-06-23 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (NRG-1)
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2721156B1 (de) 2011-06-16 2016-12-21 Ionis Pharmaceuticals, Inc. Antisense-modulierung der expression des fibroblastenwachstumsfaktor-rezeptors 4
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP3553169B1 (de) 2011-12-28 2021-11-03 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (de) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Verfahren zur herstellung heterocyclischer esterderivate
TWI702057B (zh) 2012-11-15 2020-08-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
WO2014106606A1 (en) * 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
AU2014205483B2 (en) 2013-01-10 2017-11-30 Gilead Sciences, Inc. Non-selective kinase inhibitors
CA2897538A1 (en) * 2013-01-10 2014-07-17 Pulmokine, Inc. Therapeutic indications of kinase inhibitors
ES2900492T3 (es) 2013-03-06 2022-03-17 Incyte Holdings Corp Procesos y productos intermedios para elaborar un inhibidor de JAK
RS60469B1 (sr) 2013-08-07 2020-07-31 Incyte Corp Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
JP6483714B2 (ja) 2013-10-11 2019-03-13 ローレンス エス． ジスマン， 噴霧乾燥製剤
JP6730701B2 (ja) 2013-11-14 2020-07-29 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
CA2932609A1 (en) 2013-12-05 2015-06-11 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
KR20170129757A (ko) 2015-03-25 2017-11-27 노파르티스 아게 Fgfr4 억제제로서의 포르밀화 n-헤테로시클릭 유도체
WO2018081567A1 (en) 2016-10-27 2018-05-03 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
PT3746429T (pt) 2018-01-30 2022-06-20 Incyte Corp Processos para a preparação de (1-(3-fluoro-2-(trifluorometil)isonicotinoíl)piperidin-4-ona)
EP4424328A3 (de) 2018-03-30 2024-12-04 Incyte Corporation Behandlung von hidradenitis suppurativa mit jak-hemmern
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
BR9916324A (pt) * 1998-12-17 2001-10-02 Hoffmann La Roche 4,5-pirazinoxindóis como inibidores de proteìna quinase
HUP0202682A3 (en) * 1999-09-10 2003-03-28 Merck & Co Inc Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
EP1363702A4 (de) * 2001-01-30 2007-08-22 Cytopia Pty Ltd Verfahren zur hemmung von kinasen

Also Published As

Publication number Publication date
US7122550B2 (en) 2006-10-17
IL165264A (en) 2011-07-31
EP1513821B1 (de) 2007-10-31
DE60317198T2 (de) 2008-12-04
CN1656082A (zh) 2005-08-17
IL165264A0 (en) 2005-12-18
US20060148824A1 (en) 2006-07-06
EP1513821A4 (de) 2006-05-03
CA2486183C (en) 2012-01-10
GB2392154A (en) 2004-02-25
NZ537155A (en) 2006-09-29
GB2392154B (en) 2005-01-19
CN100558715C (zh) 2009-11-11
WO2003099796A1 (en) 2003-12-04
US20040235862A1 (en) 2004-11-25
EP1513821A1 (de) 2005-03-16
ATE377004T1 (de) 2007-11-15
GB0318438D0 (en) 2003-09-10
CA2486183A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
DE60317198D1 (de) Proteinkinaseinhibitoren
DE60331187D1 (de) Kinaseinhibitoren
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
BG108181A (bg) Нови спиротрициклични производни и тяхното използване като инхибитори на фосфодиестераза-7
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
NO20054195D0 (no) Isoksazolforbindelser som inhibitorer for varmesjokkproteiner
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
NO20005237D0 (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501900A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
NO20030297L (no) Aryl sulfonamider som serotoninantagonist for behandling av fedme
EA200600455A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600456A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
NO20061302L (no) Derivater av hydroksaminsyre som metalloproteinseinbitorer
EA200600454A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200601086A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600249A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600250A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501258A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CYTOPIA RESEARCH PTY. LTD., RICHMOND, VICTORIA, AU

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: YM BIOSCIENCES AUSTRALIA PTY LTD, MELBOURNE, V, AU